Boston Partners Has $610,000 Stock Holdings in Mesa Laboratories, Inc. (NASDAQ:MLAB)

Boston Partners lessened its stake in shares of Mesa Laboratories, Inc. (NASDAQ:MLAB - Free Report) by 44.6% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 4,627 shares of the medical instruments supplier's stock after selling 3,726 shares during the period. Boston Partners owned 0.09% of Mesa Laboratories worth $610,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. FMR LLC increased its position in shares of Mesa Laboratories by 34.1% in the third quarter. FMR LLC now owns 393 shares of the medical instruments supplier's stock worth $51,000 after purchasing an additional 100 shares during the period. Quantbot Technologies LP bought a new position in Mesa Laboratories in the 3rd quarter valued at about $70,000. Amundi raised its position in shares of Mesa Laboratories by 81.6% in the 4th quarter. Amundi now owns 661 shares of the medical instruments supplier's stock valued at $91,000 after buying an additional 297 shares in the last quarter. Captrust Financial Advisors bought a new stake in shares of Mesa Laboratories during the 3rd quarter worth approximately $207,000. Finally, Berry Wealth Group LP boosted its position in shares of Mesa Laboratories by 5.3% during the 4th quarter. Berry Wealth Group LP now owns 1,657 shares of the medical instruments supplier's stock worth $219,000 after acquiring an additional 83 shares in the last quarter. 90.60% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In other news, CEO Gary M. Owens sold 21,000 shares of the stock in a transaction on Wednesday, March 19th. The stock was sold at an average price of $123.91, for a total value of $2,602,110.00. Following the completion of the transaction, the chief executive officer now directly owns 43,337 shares in the company, valued at approximately $5,369,887.67. This represents a 32.64 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 4.40% of the stock is currently owned by corporate insiders.

Remove Ads

Mesa Laboratories Price Performance

NASDAQ:MLAB traded down $3.53 during mid-day trading on Wednesday, reaching $121.89. The stock had a trading volume of 58,695 shares, compared to its average volume of 37,210. Mesa Laboratories, Inc. has a 12 month low of $83.68 and a 12 month high of $155.12. The stock has a market capitalization of $662.35 million, a PE ratio of -2.63 and a beta of 0.82. The company has a debt-to-equity ratio of 0.61, a current ratio of 0.71 and a quick ratio of 0.53. The stock has a 50-day simple moving average of $137.74 and a two-hundred day simple moving average of $129.29.

Mesa Laboratories (NASDAQ:MLAB - Get Free Report) last issued its quarterly earnings results on Tuesday, February 4th. The medical instruments supplier reported $2.07 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.41 by $0.66. Mesa Laboratories had a positive return on equity of 30.23% and a negative net margin of 104.92%. On average, equities analysts anticipate that Mesa Laboratories, Inc. will post 8 earnings per share for the current year.

Mesa Laboratories Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Monday, March 17th. Stockholders of record on Friday, February 28th were issued a $0.16 dividend. The ex-dividend date of this dividend was Friday, February 28th. This represents a $0.64 dividend on an annualized basis and a dividend yield of 0.53%. Mesa Laboratories's dividend payout ratio (DPR) is currently -1.38%.

Mesa Laboratories Profile

Mesa Laboratories, Inc develops, designs, manufactures, sells, and services life sciences tools and quality control products and services in North America, Europe, the Asia Pacific, and internationally. The Sterilization and Disinfection Control segment offers biological, chemical, and cleaning indicators, used to assess the effectiveness of sterilization decontamination, disinfection, and cleaning processes in the pharmaceutical, medical device, and healthcare industries.